Pulmospray® for Inhaled Heparin (COVID-19 ARDS)
Acute Respiratory Distress Syndrome in COVID-19
Phase 2bActive (Trial NCT04990830 completed)
Key Facts
Indication
Acute Respiratory Distress Syndrome in COVID-19
Phase
Phase 2b
Status
Active (Trial NCT04990830 completed)
Company
About Resyca
Resyca BV is a private, Netherlands-based company that has established itself as a specialist in innovative soft mist drug delivery platforms. Its core technologies, the PFSI™ (pre-filled syringe inhaler) and Pulmospray®/Ultra Soft Nasal Pump Spray systems, are designed to aerosolize liquid formulations—including sensitive biologics and high-dose drugs—for targeted lung and nasal cavity delivery. Operating as a B2B platform and development partner, Resyca collaborates with pharmaceutical companies to accelerate combination products to market, leveraging clinically validated, IP-protected devices that align with sustainability goals by avoiding propellants.
View full company profile